Treatment Outline and Clinical Outcome of Hospitalized COVID-19 Patients: Experiences from a Combined Military Hospital of Bangladesh

Authors
Sabiha Mahboob¹, Fatema Johora², Asma Akter Abbasy³, Fatiha Tasmin Jeenia⁴, Mohammad Ali⁵, Md Humayun Kabir⁶, Ferdaush Ahmed Sojib⁷, Jannatul Ferdoush⁸

Affiliations
¹Major, Medical Officer, CMH Bogura, Bogura
²Associate Professor, Department of Pharmacology & Therapeutics, Army Medical College Bogura
³Associate Professor, Department of Pharmacology & Therapeutics, Brahmanbaria Medical College
⁴Assistant Professor, Department of Pharmacology & Therapeutics, Chattogram International Medical College
⁵Specialist- Anaesthesiology, Department of Anaesthesia, Asgar Ali Hospital Ltd, Dhaka
⁶Major, Trainee in Histopathology, Armed forces Institute of Pathology, Dhaka
⁷Major, Medical officer, 101 Field ambulance, Ramu cantonment
⁸Associate Professor, Department of Pharmacology & Therapeutics, BGC Trust Medical College, Chattogram

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Treatment Outline and Clinical Outcome of Hospitalized COVID-19 Patients: Experiences from a Combined Military Hospital of Bangladesh

ABSTRACT

Background: Global knowledge of treatment and outcomes of COVID-19 has been evolving since the onset of the pandemic.

Materials and Methods: The objective of this cross-sectional study was to explore treatment and outcome of COVID-19 patients admitted in a Combined Military Hospital of Bangladesh. Data were collected from treatment records of patients of the CMH Bogura during the period of June 2020 to August 2020. Total 219 RT-PCR positive admitted patients were included as study population.

Result: Among 219 patients, 78.6% were male and 21.5% were female, mean age of patients was 34.3 ± 12.2. About 14.6% patients had one or more comorbidities. Most (83.1%) of the admitted patients were diagnosed as mild cases. Antimicrobials were used in 98.8% cases, and frequent use of doxycycline (80.4%) and ivermectine (77.2%) was found. Anticoagulant and steroid therapy were used in 42.0% and 15.5% patients respectively. O₂ therapy was required in 6.0% cases and intensive care unit (ICU) support was needed in 2.3% cases. Duration of hospital stay was 12.1 ± 4.4 days and 100% of patients were discharged from hospital. There was no single mortality during the study period.

Conclusion: High prevalence of antimicrobials use was observed among the hospitalized COVID-19 patients in this single center study. Supportive care was effective with no incidence of mortality.

Key words: Antimicrobials; Bangladesh; COVID-19; treatment; doxycycline; ivermectin; outcome.
INTRODUCTION

Coronavirus disease 2019 (COVID-19), the highly contagious viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a catastrophic effect worldwide. After the detection of the first case of this predominantly respiratory viral illness in Wuhan, Hubei Province, China, in late December 2019, SARS-CoV-2 rapidly disseminated across the world in a short span of time. The World Health Organization (WHO) has declared it as a global pandemic on March 11, 2020. Since being declared a global pandemic, the COVID-19 pandemic emerged as a major public health emergency affecting the healthcare services all over the world.

Coronavirus disease 2019 (COVID-19) is characterized by hyperinflammatory response, vascular damage, microangiopathy, angiogenesis and widespread thrombosis. Four stages of COVID-19 have been identified. The first stage is characterized by upper respiratory tract infection, the second by the onset of dyspnea and pneumonia, the third by a worsening clinical scenario dominated by a cytokine storm and the consequent hyperinflammatory state, and the fourth by death or recovery. The complex pathophysiology, pulmonary and extrapulmonary disease, and immune mediated effects make medical management more challenging than many viral illnesses. Following infection with SARS-CoV-2, some diseased individuals may remain asymptomatic or only present with mild upper respiratory symptoms, or may develop pneumonia and severe acute respiratory distress syndrome (ARDS) that requires intubation in intensive care and presents complications with an ominous outcome.

Currently, no treatment is very effective for prevention and treatment of SARS-CoV-2 infection. Several vaccines are available all over the world. Vaccination reduces the chance of infection as well as mortality and morbidity. The COVID-19 nationwide immunization campaigns in Bangladesh began on February 7, 2021, based on a set of criteria that prioritized the most vulnerable members of the population.
clinical stages of COVID-19, the classes of drugs that are mainly used include steroids, low-
molecular-weight heparins antiviral agents, plasma, and hyperimmune immunoglobulins.\textsuperscript{5,7,12,13} Unlike influenza infections and related pneumonia, a few COVID-19 patients experience an initial bacterial superinfection at admission due to pneumococci, other streptococci or staphylococci and require antimicrobial therapy.\textsuperscript{14,15} Management and outcome of COVID-19 varied from country to country.\textsuperscript{16} There are few available data in this context from Bangladesh.\textsuperscript{17,18,19} Hence, the present study was conducted to discuss treatment outline and clinical outcome of COVID-19 patients admitted in a combined military hospital of Bangladesh.
MATERIALS & METHODS

This retrospective cross-sectional study was conducted in a Combined Military Hospital (CMH) Bogura of Bangladesh from June 2020 to August 2020 with the aim to explore treatments and outcomes of admitted COVID-19 patients. Ethical approval was taken from Institutional Review Board (IRB) of CMH Bogura. Data were collected from treatment records of COVID-19 patients of CMH Bogura during the period of June 2020 to August 2020. Investigators collected retrospective data from chronological register and treatment records kept in the Record Room of hospital. Data collection started from the most recently registered in-patient records to gradually backward manner. RT-PCR positive admitted COVID-19 patients of all age groups and sexes were included as study population. RT-PCR negative but radiologically suggestive cases of COVID-19 patients were excluded from the study. Treatment sheets of total 219 patients were included in this study. A review form was used for data collection. For maintenance of anonymity, an identification number was provided at top of the front page of the treatment sheet where confirmed clinical diagnosis and patient profile were mentioned. Data was compiled, presented and analyzed using Microsoft Excel 2007, and was expressed as percentage.
Results

Table I showing out of 219 patients, 78.6% were male and 21.5% were female. Mean age (years) of patients was 34.3 ± 12.2. Most (85.4%) of the patients had no comorbidity.

Table I  Demographic characteristics of admitted COVID-19 patients

<table>
<thead>
<tr>
<th>Gender</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>172</td>
<td>78.6%</td>
</tr>
<tr>
<td>Female</td>
<td>47</td>
<td>21.5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>34.26 ± 12.13</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comorbidities</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td>32</td>
<td>14.6%</td>
</tr>
</tbody>
</table>

Most (83.1%) of the hospitalized patients were diagnosed as mild cases (Figure 1).

![Figure1: Diagnosis of hospitalized COVID-19 patients](https://doi.org/10.1101/2022.03.01.22271740)
<table>
<thead>
<tr>
<th>Variables</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paracetamol</td>
<td>204</td>
<td>93.2</td>
</tr>
<tr>
<td>Antihistamine</td>
<td>185</td>
<td>84.5</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>184</td>
<td>84.1</td>
</tr>
<tr>
<td>Vitamin D</td>
<td>187</td>
<td>85.4</td>
</tr>
<tr>
<td>Vitamin B complex</td>
<td>28</td>
<td>12.8</td>
</tr>
<tr>
<td>Calcium</td>
<td>148</td>
<td>67.6</td>
</tr>
<tr>
<td>Zinc</td>
<td>106</td>
<td>48.4</td>
</tr>
<tr>
<td>Antitussive</td>
<td>11</td>
<td>5.0</td>
</tr>
<tr>
<td>Antiemetics</td>
<td>25</td>
<td>11.4</td>
</tr>
<tr>
<td>Antiulcerants</td>
<td>169</td>
<td>77.2</td>
</tr>
<tr>
<td>Aspirin</td>
<td>32</td>
<td>14.6</td>
</tr>
<tr>
<td>Antihypertensive</td>
<td>22</td>
<td>10.1</td>
</tr>
<tr>
<td>Antidiabetic</td>
<td>11</td>
<td>5.0</td>
</tr>
<tr>
<td>Montelukast</td>
<td>185</td>
<td>84.5</td>
</tr>
<tr>
<td>B2-agonist</td>
<td>54</td>
<td>24.7</td>
</tr>
<tr>
<td>Doxyphyline</td>
<td>69</td>
<td>31.5</td>
</tr>
<tr>
<td>Sedatives</td>
<td>29</td>
<td>13.3</td>
</tr>
<tr>
<td>ORS</td>
<td>20</td>
<td>9.2</td>
</tr>
<tr>
<td>Intravenous fluid</td>
<td>11</td>
<td>5.1</td>
</tr>
</tbody>
</table>

Most (98.8%) of the patients received 1 or more antimicrobial agents. 42.0% patients received anticoagulant drugs, where 15.5% received steroid therapy.
Figure 2: Proportion of patients received anticoagulant, steroids and antimicrobial agents

Figure 3 showed that doxycycline (80.4%) was the frequently used antimicrobials followed by ivermectine (77.2%). Other antibiotics (amoxillin, ceftriaxone, cefuroxime, meropenem, levofloxacin, moxifloxacin etc) were used in alone or combination in 35.6% cases.

**Figure 3** Proportion of antimicrobials used in COVID-19

Only 6.0% of patients required O2 therapy and 2.3% patients were needed intensive care unit (ICU) support (**Figure 4 & 5**).
Table III showed duration of hospital stay was 12.1 ± 4.4 days. All 219 patients (100%) were discharged from hospital. There was not a single case of death or referring to higher center during the study period.
### Table III: Hospital course and outcome of admitted COVID-19 patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of hospital stay (days)</td>
<td>12.1 ± 4.4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discharge</td>
<td>219</td>
<td>100</td>
</tr>
<tr>
<td>Transferred out</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Death</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
DISCUSSION

For several months, COVID-19 pandemic has put enormous burden on healthcare system all over the world. Highly contagious nature, complex pathogenicity and absence of a definitive therapeutic agent all are making this pandemic a long run for human being. Initially physicians tried ‘repurposing’ of several existing therapeutic molecules along with symptomatic treatment to combat COVID-19. At the same time, several clinical trials were conducted to study the safety and effectiveness of several repurposed drugs for COVID-19 treatment. Later on countries were started to develop clinical guidelines for management of coronavirus with the support of World Health Organization. Current study was conducted to assess treatment outline and clinical outcome of hospitalized COVID-19 patients of a combined military hospital during the first wave of COVID-19 pandemic.

Present study revealed that 98.8% of the admitted patients received one or more antimicrobial agents although most of the cases were mild disease. Despite of no recommendation of antimicrobial for treatment of mild cases in clinical guidelines, higher usage of antimicrobials in COVID-19 patients was observed in previous studies done in home and abroad. Increased prescribing of antimicrobials in this pandemic is alarming. COVID-19 patients could receive antimicrobial therapy for several reasons. Firstly, clinical scenario of COVID-19 is confusing and difficult to distinguish from bacterial pneumonia. As a result, almost 70% of hospitalized COVID-19 patients receive empiric broad-spectrum antibiotic therapy due to lack of confirm microbiological diagnosis. Secondly, prevention of presumed secondary bacterial infections is another reason of antimicrobials prescribing in COVID-19 patients although 16% of hospitalized develop secondary bacterial infection, where antibiotics are needed. Injudicious use of antimicrobials effective against MRSA or antipseudomonal
antimicrobials in critical COVID-19 patients could worsen the current situation of AMR.\textsuperscript{26} Doxycycline and ivermectine were frequently used antimicrobials and this finding is contrary to related literatures as previous researchers found azithromycin as frequently prescribed agent.\textsuperscript{24,27} Ahmed et al described the administration of either hydroxychloroquine, doxycycline, azithromycin or favipiravir alone or in combination to all hospitalized patients in another combined military hospital of Bangladesh.\textsuperscript{19} One study from United States found significantly increased dispensing of ivermectin although it was not is not authorized or approved by FDA for prevention or treatment of COVID-19.\textsuperscript{28} Nasir et al revealed ivermectin and doxycycline were frequently consumed as self-medication during the first wave of pandemic. Lower usage of remdesivir, favipirapir and hydroxychloroquine was observed in current study that was similar to previous studies done in different countries including Bangladesh.\textsuperscript{22,24,27,30,31} But two recent studies done in Bangladesh found higher usage of these agents in certain percentage of patients having comorbidities.\textsuperscript{17,18} Steroids have the potential to prevent an extended cytokine response and may accelerate resolution of pulmonary and systemic inflammation in pneumonia. Methylprednisolone, may improve dysregulated immune response caused by sepsis (possible complication of infection with COVID-19) and hypotension. Dexamethasone has been reported to reduce the duration of mechanical ventilation. Long-term glucocorticoid therapy has displayed significant improvement in indices of alveolar–capillary membrane permeability and mediators of inflammation and tissue repair, and reduction of duration of mechanical ventilation. In this study, steroid was prescribed to moderate, severe or critical COVID patients and this practice was concordance with national guideline.\textsuperscript{13} Two similar studies done in Bangladesh revealed higher usage of
steroid. Increased age, comorbidities and severity of disease were seen among the population of those two studies.\textsuperscript{17, 18}

Based on available evidence, it is reasonable to administer venous thromboembolism prophylaxis with either a low molecular weight or unfractionated heparin in hospitalized patients. In patients with rapidly progressing respiratory deterioration or where clinical judgment suggests thrombosis, treatment doses of anticoagulants may be considered.\textsuperscript{32, 33} In this study, 42\% patients received anticoagulant therapy and that was similar to Soni et al.\textsuperscript{34} Where study done by Islam et al showed 100\% patients had thromboprophylaxis as they treated severe and critical illness more than this studied hospital.\textsuperscript{17}

Montelukast, a leukotrine receptor antagonist, mainly used as a complementary therapy in adults in addition to inhaled corticosteroids in bronchial asthma and COPD.\textsuperscript{35} It is also known to decrease the frequency and severity of wheezing after an upper respiratory tract infection caused by adenovirus, influenza, metapneumovirus or coronavirus.\textsuperscript{36} More effectiveness could be find in patients with comorbidities such as bronchial asthma, diabetes, sleep apnea, smoking, obesity, or symptomatic atherosclerotic lesions.\textsuperscript{35} In current study, 84.5\% patients received montelukast although only 14.6\% had comorbidities. There was no available study to compare this finding. There was no recommendation of montelukast in national guideline.\textsuperscript{13} Antipyretics, antihistamines as symptomatic treatment and calcium, zinc, vitamin C, vitamin D were used as supplemental therapy in this study like other related studies.\textsuperscript{17, 18, 19, 34}

Present study showed that 5.9\% patients required oxygen therapy and that was similar to one study conducted in Bangladesh.\textsuperscript{19} Higher requirement of oxygen was seen in other studies conducted in Bangladesh and India.\textsuperscript{18, 34, 39} In this study, 2.3\% patients required intensive care and that was concurrent to three relevant studies.\textsuperscript{19, 34, 37} But findings of Ali et al (8.7\%), Soni et al
(52%) and Hossain et al (24.9%) were different from current study.\textsuperscript{18,34,39} Younger age group, less comorbidity and mild cases might be the reason of less requirement of oxygen therapy and intensive care in our study.\textsuperscript{19,36}

In current study, duration of hospital stay was 12.1 ± 4.4 days and that was different from earlier study conducted in Bangladesh. Islam et al showed hospital stay was less than 10 days in maximum cases although most of the cases were severe and critical.\textsuperscript{17} Despite having 83% mild cases with longer hospital stay indicates difference in policy of studied hospitals. In our study, there was no single incidence of mortality, 100% patients were discharged from hospital. 0.03% and 1% mortality were observed in two studies conducted in Bangladesh.\textsuperscript{18,19} Another two studies done in Bangladesh found 4.7% and 19.3% mortality respectively.\textsuperscript{17,39} 1.4% and 2.6% mortality were observed in Indian studies.\textsuperscript{34,37} Younger age group, less comorbidity and mild form of disease favor good outcome of our patients.\textsuperscript{17,39}
CONCLUSION

High prevalence of antimicrobials use was observed among the hospitalized COVID-19 patients in current study. Supportive care was effective with no incidence of mortality.
REFERENCE


12. McFee RB. COVID-19: Therapeutics and interventions currently under consideration. Dis


